Zika Virus Neutralizing Antibody Responses Elicited by Vaccination or Infection.

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Zika virus (ZIKV) emerged significantly in 2015-2016, causing widespread Congenital Zika Syndrome.
• Challenges in vaccine development include a lack of protection correlates and a decline in ZIKV transmission.
• Understanding neutralizing antibody (nAb) responses to natural infection is crucial for evaluating vaccine candidates.

Purpose of the Study:

• To compare anti-ZIKV nAb responses from natural infection versus the TAK-426 vaccine.
• To assess vaccine efficacy using a standardized neutralizing antibody assay across diverse populations.

Main Methods:

• Comparison of ZIKV nAb responses in individuals with natural ZIKV infection and TAK-426 vaccine recipients.
• Utilized a consistent neutralizing antibody assay for all participants.
• Analyzed nAb titers at various time points post-infection or vaccination.

Main Results:

• Natural ZIKV infection induced higher nAb levels than the TAK-426 vaccine at all measured time points.
• Vaccine-elicited nAb titers met protection thresholds in flavivirus-naive and -primed individuals one month post-second dose.
• While antibody kinetics showed similar patterns (peak, decline, stabilization), vaccine non-inferiority was not established.

Conclusions:

• The current TAK-426 vaccine formulation may not provide adequate protection against ZIKV in endemic regions.
• Further investigation into booster doses for the TAK-426 vaccine is warranted.
• Understanding nAb responses is key to developing effective ZIKV vaccines.